ICR Hosts SAB Biotherapeutics CEO Eddie Sullivan on the Welcome to the Arena Podcast
ICR , a leading strategic communications and advisory firm, is pleased to announce that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, recently appeared on Episode 67 of ICR’s “Welcome to the Arena” podcast.
- ICR , a leading strategic communications and advisory firm, is pleased to announce that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, recently appeared on Episode 67 of ICR’s “Welcome to the Arena” podcast.
- Welcome to the Arena is hosted by Tom Ryan, Co-Founder & CEO of ICR.
- Tom spoke with Eddie about SAB's polyclonal antibody research and their unique use of cows, the future of fighting diseases, the biggest challenges in biotech, and more.
- The Welcome to the Arena podcast has featured discussions with CEOs, CFOs, financial analysts, members of the media, investment bankers, private equity executives and others who influence and create value for public and private-equity backed companies.